Noxopharm (NOX:ASX) announces that Australian patent application No. 2016401508 has been allowed by the Australian Patent Office. The patent claims are directed to a suppository formulation including idronoxil and the allowed claims provide broad coverage for Veyonda® as a therapeutic.
For more information, download the attached PDF.
Download this document
